| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958915 | VANSEN PHARMA | Antibacterial composition for oral administration |
Oct, 2016
(7 years ago) | |
Spectracef is owned by Vansen Pharma.
Spectracef contains Cefditoren Pivoxil.
Spectracef has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Spectracef are:
- US5958915
Spectracef was authorised for market use on 29 August, 2001.
Spectracef is available in tablet;oral dosage forms.
The generics of Spectracef are possible to be released after 14 October, 2016.
Drugs and Companies using CEFDITOREN PIVOXIL ingredient
Market Authorisation Date: 29 August, 2001
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
SPECTRACEF family patents
